<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-15T11:11:46+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【招募患者】一项在复发或难治性B细胞非霍奇金淋巴瘤患者中评估REGN1979的抗肿瘤活性和安全性的开放性研究</title>
    <updated>2020-11-15T08:33:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/eQBtOQTMXnycIlEYJOTp9w</id>
    <link href="https://mp.weixin.qq.com/s/eQBtOQTMXnycIlEYJOTp9w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价 ICP-022治疗初治的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的随机、对照、开放性、多中心III期临床试验</title>
    <updated>2020-11-14T08:38:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-14:/s/esLbAOxLzZeo-xnOuCa04w</id>
    <link href="https://mp.weixin.qq.com/s/esLbAOxLzZeo-xnOuCa04w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【科济CAR-T招募3】评价CT041自体CART细胞注射液在晚期胃/食管胃结合部腺癌和胰腺癌中的有效性、安全性与细胞代谢动力学</title>
    <updated>2020-11-13T07:29:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/ZtRaCmASZ4OKgkZJ04EJDw</id>
    <link href="https://mp.weixin.qq.com/s/ZtRaCmASZ4OKgkZJ04EJDw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在食管鳞癌中比较阿替利珠单抗+TIRAGOLUMAB联合紫杉醇+顺铂作为一线治疗的III期、随机、双盲临床研究</title>
    <updated>2020-11-12T07:45:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/b0VoabvPrDQ-4rV7cQA0HQ</id>
    <link href="https://mp.weixin.qq.com/s/b0VoabvPrDQ-4rV7cQA0HQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价在晚期实体瘤中给予Lurbinectedin的安全性、PK特征及有效性的单臂、开放、剂量递增及扩展的I期临床研究</title>
    <updated>2020-11-11T08:17:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/996Wu0nU9mCkqsCZmnboZg</id>
    <link href="https://mp.weixin.qq.com/s/996Wu0nU9mCkqsCZmnboZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【普瑞金CAR-T招募1】靶向BCMA的嵌合抗原受体T细胞注射液在BCMA阳性的复发/难治多发性骨髓瘤的I期临床研究</title>
    <updated>2020-11-10T09:11:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/TsECEZIJbyzKeiozsubNlQ</id>
    <link href="https://mp.weixin.qq.com/s/TsECEZIJbyzKeiozsubNlQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【宝船PD-L1招募患者2】全人源抗PD-L1抗体治疗泌尿及男性生殖系统肿瘤有效性和安全性的、单臂、开放、多中心、II期临床研究</title>
    <updated>2020-11-09T08:06:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/ZYNlpPHPSn4FpJnkDVNX7w</id>
    <link href="https://mp.weixin.qq.com/s/ZYNlpPHPSn4FpJnkDVNX7w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价AST-3424 治疗复发难治性急淋白血病的安全性、PK、初步疗效以及疗效与AKR1C3 酶表达相关性的临床研究</title>
    <updated>2020-11-08T07:31:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/53v0ajd7by5cyAnl0sj06g</id>
    <link href="https://mp.weixin.qq.com/s/53v0ajd7by5cyAnl0sj06g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在EGFR阳性晚期非小细胞肺癌患者中评估MRG003有效性和安全性的II期研究</title>
    <updated>2020-11-06T07:49:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/jLieSZIBcpilBm4lRrnD_w</id>
    <link href="https://mp.weixin.qq.com/s/jLieSZIBcpilBm4lRrnD_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【默沙东PD-1招募29】帕博利珠单抗联合同步放化疗序贯帕博利珠单抗联合奥拉帕利用于治疗III期NSCLC的III期研究</title>
    <updated>2020-11-05T14:12:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/JYwBcHgSxAQGXxXQRrfOYg</id>
    <link href="https://mp.weixin.qq.com/s/JYwBcHgSxAQGXxXQRrfOYg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>